reference/10197053

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10197053

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
endingPage	497
issn	0090-8258
issueIdentifier	2
pageRange	491-497
publicationName	Gynecologic Oncology
startingPage	491
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a083735aebc9a325683091959d090667 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_1d33dbd06de50e8e836027ea8a1f4aeb
bibliographicCitation	Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020 Nov;159(2):491–7. doi: 10.1016/j.ygyno.2020.08.013. PMID: 32951894.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_66288565caf24cb91d36ca98cdad6041 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c2c559d3025927f4086457c109d57421 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_332dddfd39339f90d5968df7ef4437f4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5a39510442e6654cc3ca0a3ecd36f37 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d5bc388ddceba50e32559fee551d4c5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5244efbd56aa6e190931b0b5a28e2446 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_30b46f84648890b58967cb56b6320652 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb530bad5ad88764ee0c10914aa739ce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab4c65f3b0d7e0dc888bb46df00371f1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dacddd66ce34b970d9d5249d63e51e77
date	202011
identifier	https://doi.org/10.1016/j.ygyno.2020.08.013 https://pubmed.ncbi.nlm.nih.gov/32951894
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3932 https://portal.issn.org/resource/ISSN/0090-8258
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
discusses	http://id.nlm.nih.gov/mesh/M000601132 http://id.nlm.nih.gov/mesh/M0028758 http://id.nlm.nih.gov/mesh/M0537510 http://id.nlm.nih.gov/mesh/M0549409 http://id.nlm.nih.gov/mesh/M0016766 http://id.nlm.nih.gov/mesh/M0242709 http://id.nlm.nih.gov/mesh/M0475257 http://id.nlm.nih.gov/mesh/M0016884
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000077216Q000188 http://id.nlm.nih.gov/mesh/D000067856Q000191 http://id.nlm.nih.gov/mesh/D060046Q000191 http://id.nlm.nih.gov/mesh/D010051Q000188 http://id.nlm.nih.gov/mesh/D010793Q000191 http://id.nlm.nih.gov/mesh/D010879Q000191
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D010879Q000009 http://id.nlm.nih.gov/mesh/D000067856Q000009 http://id.nlm.nih.gov/mesh/D010051Q000401 http://id.nlm.nih.gov/mesh/D000077216Q000401 http://id.nlm.nih.gov/mesh/D010051Q000235 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D018095 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D014481 http://id.nlm.nih.gov/mesh/D010793Q000009 http://id.nlm.nih.gov/mesh/D003362 http://id.nlm.nih.gov/mesh/D000077216Q000235 http://id.nlm.nih.gov/mesh/D000067856Q000008 http://id.nlm.nih.gov/mesh/D019313 http://id.nlm.nih.gov/mesh/D019057 http://id.nlm.nih.gov/mesh/D010879Q000008 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D024682 http://id.nlm.nih.gov/mesh/D010793Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_6f3ef4a5ab86c1588ba1fc89f4c730bb http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23725625 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_533622b82f51bc5431a771c088f3bdd9

Total number of triples: 66.